1 Bally L, Thabit H, Hartnell S, Andereggen E, Ruan Y, Wilinska ME, et al. Closed-loop insulin delivery for glycemic control in noncritical care. N Engl J Med. 2018;379(6):547–56.
2 Boughton CK, Bally L, Martignoni F, Hartnell S, Herzig D, Vogt A, et al. Fully closed-loop insulin delivery in inpatients receiving nutritional support: a two-centre, open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(5):368–77.
3 Boughton CK, Tripyla A, Hartnell S, Daly A, Herzig D, Wilinska ME, et al. Fully automated closed-loop glucose control compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis: an open-label, randomized crossover trial. Nat Med. 2021;27(8):1471–6.
4 Rosenstock J, Bajaj HS, Janež A, Silver R, Begtrup K, Hansen MV, et al. Once-weekly insulin for type 2 diabetes without previous insulin treatment. N Engl J Med. 2020;383(22):2107–16.
5 Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al. Tirzepatide versus Semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503–15.